-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, March 31, News Livzon Group ushered in a bumper performance in 2020, operating income exceeded 10 billion for the first time, a year-on-year increase of 12.
10%; net profit was 1.
715 billion yuan, a year-on-year increase of 31.
63%, and expected cash dividends of 1.
165 billion yuan, a year-on-year increase An increase of 8.
39%.
In recent years, Livzon Group has entered a new stage of innovation-driven development.
The innovative drug ilaprazole and leuprolide acetate microspheres for injection of high-barrier complex preparations have continued to grow rapidly, and have now grown into more than 1 billion varieties.
Become a powerful engine for the company's rapid development.
In 2021, the group's multiple biological drugs and microsphere varieties will enter the harvest period.
10%; net profit was 1.
715 billion yuan, a year-on-year increase of 31.
63%, and expected cash dividends of 1.
165 billion yuan, a year-on-year increase An increase of 8.
39%.
In recent years, Livzon Group has entered a new stage of innovation-driven development.
The innovative drug ilaprazole and leuprolide acetate microspheres for injection of high-barrier complex preparations have continued to grow rapidly, and have now grown into more than 1 billion varieties.
Become a powerful engine for the company's rapid development.
In 2021, the group's multiple biological drugs and microsphere varieties will enter the harvest period.
Revenue breaks tens of billions for the first time, and the exclusive variety "Rocket-style" soars
In 2020, the sales revenue of Livzon Group's chemical preparation products was 5.
4 billion yuan, an increase of 9.
56% year-on-year, accounting for 51.
64% of total revenue; the sales revenue of traditional Chinese medicine preparation products was 1.
2 billion yuan, a year-on-year decrease of 5.
78%, accounting for 11.
54% of total revenue.
%; The sales revenue of APIs and intermediate products was 2.
4 billion yuan, an increase of 3.
84% year-on-year, accounting for 23.
32% of total revenue; the sales revenue of diagnostic reagents and equipment was 1.
4 billion yuan, an increase of 83.
29% year-on-year, accounting for 13.
22% of total revenue %.
4 billion yuan, an increase of 9.
56% year-on-year, accounting for 51.
64% of total revenue; the sales revenue of traditional Chinese medicine preparation products was 1.
2 billion yuan, a year-on-year decrease of 5.
78%, accounting for 11.
54% of total revenue.
%; The sales revenue of APIs and intermediate products was 2.
4 billion yuan, an increase of 3.
84% year-on-year, accounting for 23.
32% of total revenue; the sales revenue of diagnostic reagents and equipment was 1.
4 billion yuan, an increase of 83.
29% year-on-year, accounting for 13.
22% of total revenue %.
In recent years, Franc Group's diagnostics business segment revenues rising fast, in order to further enhance the profitability and competitiveness, the company decided to split Franc reagents to the Shenzhen Stock Exchange GEM board listed, the latest news shows, Franc reagent respectively in 2020 In November 2015 and February 2021, we went through the counseling filing registration and submitted the first mid-term counseling filing report.
Table 1: Livzon Group's preparation products with sales exceeding 100 million yuan in 2020 (unit: million yuan)
Source: Company Annual Report
In 2020, the company's sales revenue from multiple preparations showed a skyrocketing trend: the exclusive innovative drug ilaprazole successfully entered the 1 billion lineup, and sales revenue increased by 81.
20%.
Among them, the sales revenue of ilaprazole enteric-coated tablets was 950 million yuan, an increase of 8.
84% year-on-year; ilaprazole sodium for injection was approved for listing in 2018 and successfully entered the national medical insurance catalog in 2019, and the sales revenue that year broke 1 Billion yuan, an increase of 667.
09% year-on-year, and sales revenue in 2020 will be 820 million yuan, an increase of 672.
61% year-on-year The rapid growth for two consecutive years has not stopped the Livzon Group.
It is reported that the clinical trial of the new indication of ilaprazole sodium for injection "prevention of stress ulcer bleeding in critically ill patients" has been awarded the NMPA in December 2020.
Approved; in addition, the company revealed that it will invest 200 million yuan in the "in-depth development and industrialization upgrade project of ilaprazole series of innovative products" in the next four years.
This exclusive product is expected to continue to grow and become stronger.
20%.
Among them, the sales revenue of ilaprazole enteric-coated tablets was 950 million yuan, an increase of 8.
84% year-on-year; ilaprazole sodium for injection was approved for listing in 2018 and successfully entered the national medical insurance catalog in 2019, and the sales revenue that year broke 1 Billion yuan, an increase of 667.
09% year-on-year, and sales revenue in 2020 will be 820 million yuan, an increase of 672.
61% year-on-year The rapid growth for two consecutive years has not stopped the Livzon Group.
It is reported that the clinical trial of the new indication of ilaprazole sodium for injection "prevention of stress ulcer bleeding in critically ill patients" has been awarded the NMPA in December 2020.
Approved; in addition, the company revealed that it will invest 200 million yuan in the "in-depth development and industrialization upgrade project of ilaprazole series of innovative products" in the next four years.
This exclusive product is expected to continue to grow and become stronger.
Figure 1: The specific investment plan for the in-depth development and industrialization upgrade of ilaprazole series of innovative products (unit: ten thousand yuan)
Source: Company announcement
Antiviral particles are the exclusive proprietary Chinese medicine product of Sichuan Everbright Pharmaceutical, a subsidiary of Sichuan Everbright Pharmaceutical.
This product has been included in the guidelines for the diagnosis and treatment of new coronary pneumonia during the epidemic.
The company organized a number of online academic promotion activities, and the product coverage of chain pharmacies and other terminals continued to expand.
2020 The sales of anti-viral particles grew against the current trend, with an increase of over 50%.
This product has been included in the guidelines for the diagnosis and treatment of new coronary pneumonia during the epidemic.
The company organized a number of online academic promotion activities, and the product coverage of chain pharmacies and other terminals continued to expand.
2020 The sales of anti-viral particles grew against the current trend, with an increase of over 50%.
Since the medical insurance of Shenqi Fuzheng injection, the exclusive Chinese patent medicine, was restricted in 2017, the company's traditional Chinese medicine preparations segment revenue began to decline, and the growth rates from 2018 to 2020 were -25.
07%, -16.
39%, and -5.
78%, respectively.
Thanks to the pull of anti-viral particles, performance is picking up.
On March 22, Livzon Group announced the acquisition of a 40% stake in Tianjin Tongrentang for 724 million yuan, hoping to cooperate with it in the development of Chinese medicine business.
According to the data of Minai.
com, it is in the public hospitals of cities in China and county-level public hospitals .
Hospitals, urban communities and township health centers (Chinese public medical institutions for short) terminals, Tianjin Tongrentang’s proprietary Chinese medicine products mainly involve drugs for diseases such as the urinary system, cardiovascular and cerebrovascular, respiratory systems, and musculoskeletal systems .
At present, the company has launched counseling on the market.
In the future, Livzon Group can also realize corresponding investment income through its cash dividends or initial public offerings.
07%, -16.
39%, and -5.
78%, respectively.
Thanks to the pull of anti-viral particles, performance is picking up.
On March 22, Livzon Group announced the acquisition of a 40% stake in Tianjin Tongrentang for 724 million yuan, hoping to cooperate with it in the development of Chinese medicine business.
According to the data of Minai.
com, it is in the public hospitals of cities in China and county-level public hospitals .
Hospitals, urban communities and township health centers (Chinese public medical institutions for short) terminals, Tianjin Tongrentang’s proprietary Chinese medicine products mainly involve drugs for diseases such as the urinary system, cardiovascular and cerebrovascular, respiratory systems, and musculoskeletal systems .
At present, the company has launched counseling on the market.
In the future, Livzon Group can also realize corresponding investment income through its cash dividends or initial public offerings.
Livzon Group has entered a harvest period in the field of neurological drugs.
The sales revenue of the first domestic imitation fluvoxamine maleate tablets and the exclusive product piperopilone hydrochloride tablets will increase by 33.
00% and 101.
78% in 2020.
Piperone hydrochloride tablets are a new product in the 2019 National Medical Insurance Catalog.
The sales revenue that year was about 50 million yuan, and it will break through the 100 million yuan mark in 2020.
Brokers predict that neurological drugs are expected to become another independent specialty line besides the company's assisted reproduction.
The sales revenue of the first domestic imitation fluvoxamine maleate tablets and the exclusive product piperopilone hydrochloride tablets will increase by 33.
00% and 101.
78% in 2020.
Piperone hydrochloride tablets are a new product in the 2019 National Medical Insurance Catalog.
The sales revenue that year was about 50 million yuan, and it will break through the 100 million yuan mark in 2020.
Brokers predict that neurological drugs are expected to become another independent specialty line besides the company's assisted reproduction.
R&D investment of nearly 1 billion, innovative biological drugs, high-barrier complex preparations welcome a bumper period
In 2020, the total R&D investment of Livzon Group is about 990 million yuan, an increase of 19.
55% year-on-year, and the proportion of the group's total revenue has increased to 9.
41%; the number of R&D personnel has increased by 24.
97% over 2019, and the proportion of R&D personnel has also increased to 10.
89 %.
Livzon Group continues to promote product innovation and upgrading, focusing on unmet clinical needs, focusing on innovative drugs and high-barrier complex preparations.
At present, R&D projects are progressing in an orderly manner, and the harvest period for innovation and transformation is approaching.
55% year-on-year, and the proportion of the group's total revenue has increased to 9.
41%; the number of R&D personnel has increased by 24.
97% over 2019, and the proportion of R&D personnel has also increased to 10.
89 %.
Livzon Group continues to promote product innovation and upgrading, focusing on unmet clinical needs, focusing on innovative drugs and high-barrier complex preparations.
At present, R&D projects are progressing in an orderly manner, and the harvest period for innovation and transformation is approaching.
Table 2: The latest situation of Livzon Group's focus on researching innovative biological drugs
Source: China Drug Clinical Trial Publicity Library of Meinenet
At present, the Livzon Group’s biopharmaceutical platform has focused on a number of core projects.
Among them, the recombinant human chorionic gonadotropin for injection that has been declared for listing has completed the production site verification and registration inspection.
It is expected to win the first domestic one this year, and it is also registered overseas.
During the simultaneous development, the company stated that it has made preparations for the listing of the product and the post-listing marketing work, and the market potential is worth looking forward to.
Among them, the recombinant human chorionic gonadotropin for injection that has been declared for listing has completed the production site verification and registration inspection.
It is expected to win the first domestic one this year, and it is also registered overseas.
During the simultaneous development, the company stated that it has made preparations for the listing of the product and the post-listing marketing work, and the market potential is worth looking forward to.
Recombinant humanized anti-human IL-6R monoclonal antibody injection has all entered the phase III clinical trial group, and the recombinant humanized anti-PD-1 monoclonal antibody for injection has entered the phase II clinical trial.
In addition, the company announced on March 24 that the The "recombinant new coronavirus fusion protein vaccine" developed by Rizumab has obtained clinical approval, which is expected to help the company improve its market position in the field of biopharmaceuticals.
It is reported that Livzon Group is also continuously advancing the construction of ADC technology platform and new CAR-T technology platform, and it is expected to launch related new products in the future.
In addition, the company announced on March 24 that the The "recombinant new coronavirus fusion protein vaccine" developed by Rizumab has obtained clinical approval, which is expected to help the company improve its market position in the field of biopharmaceuticals.
It is reported that Livzon Group is also continuously advancing the construction of ADC technology platform and new CAR-T technology platform, and it is expected to launch related new products in the future.
Table 3: The latest situation of Livzon Group's microsphere products under development
Source: China Drug Clinical Trial Publicity Library of Meinenet
The sales revenue of Livzon Group's first high-barrier complex preparation injection leuprorelin acetate microspheres exceeded 1 billion yuan for the first time in 2020.
It is the market leading brand of this variety.
The supplementary application for consistency evaluation is currently under review and approval.
It is the market leading brand of this variety.
The supplementary application for consistency evaluation is currently under review and approval.
The dazzling transcript stimulated new impetus for the company’s research and development.
Triptorelin acetate microspheres for injection (1 month sustained release) are in the phase III clinical trial data compilation stage, and octreotide acetate microspheres for injection (1 month sustained release) are in the stage of data compilation.
Release) BE trials have started, and the two major products are expected to be approved for marketing in 2022; Aripiprazole Microspheres for Injection (1 month sustained release) are undergoing clinical trials, and Leuprolide Acetate Microspheres for Injection (3 (Monthly release) Phase I clinical trials are carried out as planned, and Phase III clinical trials have completed genetic filing.
.
.
As the company's microsphere products are successively listed, Livzon Group's domestic leading position in this field will become more prominent.
Triptorelin acetate microspheres for injection (1 month sustained release) are in the phase III clinical trial data compilation stage, and octreotide acetate microspheres for injection (1 month sustained release) are in the stage of data compilation.
Release) BE trials have started, and the two major products are expected to be approved for marketing in 2022; Aripiprazole Microspheres for Injection (1 month sustained release) are undergoing clinical trials, and Leuprolide Acetate Microspheres for Injection (3 (Monthly release) Phase I clinical trials are carried out as planned, and Phase III clinical trials have completed genetic filing.
.
.
As the company's microsphere products are successively listed, Livzon Group's domestic leading position in this field will become more prominent.
10 million to mention the first imitation in China, the "national procurement special train" is expected to get on the train?
Table 4: Status of Livzon Group's approved products in 2020
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In 2020, Livzon Group’s generic drugs ushered in a number of good news: Dantrolene sodium for injection and mixed glycoelectrolyte injection were approved for marketing, and tinidazole tablets and amlodipine besylate capsules were approved for consistency evaluation.
After 10 years of research and development, dantrolene sodium for injection was applied for the listing of 3 types of generics in February 2019.
It was included in the priority review in April of the same year.
The reason was that it was a “rare disease drug”.
In October 2020, it won the first imitation in China.
Symptoms are used to prevent and treat malignant high fever.
Malignant hyperthermia is a rare disease.
In the absence of specific treatment drugs, general clinical cooling measures are difficult to control the increase in body temperature, which can eventually lead to death of the patient.
It is reported that the Livzon Group has invested about 17.
223 million yuan in research and development expenses in the dantrolene sodium injection project.
It was included in the priority review in April of the same year.
The reason was that it was a “rare disease drug”.
In October 2020, it won the first imitation in China.
Symptoms are used to prevent and treat malignant high fever.
Malignant hyperthermia is a rare disease.
In the absence of specific treatment drugs, general clinical cooling measures are difficult to control the increase in body temperature, which can eventually lead to death of the patient.
It is reported that the Livzon Group has invested about 17.
223 million yuan in research and development expenses in the dantrolene sodium injection project.
Table 5: Status of generic drugs (except Microspheres) under review by Livzon Group since 2019
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In 2020, the company declared cetrorelix acetate for injection and voriconazole for injection (0.
2g) to be marketed.
Cetrorelix is a synthetic gonadotropin releasing hormone antagonist.
The original research company is Merck Serono.
The disease is to prevent premature ovulation for patients undergoing controlled ovarian stimulation, and then carry out egg collection and assisted reproductive technology treatment.
It has been listed in 45 countries including Europe and entered the Chinese market in 2010.
The original product will be in China in 2019.
The terminal sales of public medical institutions are close to 250 million yuan.
Shenzhen Hanyu Pharmaceutical's 6 types of imitations were approved in 2018, and Livzon Group declared for listing under the new classification, which is expected to win the first domestic review.
2g) to be marketed.
Cetrorelix is a synthetic gonadotropin releasing hormone antagonist.
The original research company is Merck Serono.
The disease is to prevent premature ovulation for patients undergoing controlled ovarian stimulation, and then carry out egg collection and assisted reproductive technology treatment.
It has been listed in 45 countries including Europe and entered the Chinese market in 2010.
The original product will be in China in 2019.
The terminal sales of public medical institutions are close to 250 million yuan.
Shenzhen Hanyu Pharmaceutical's 6 types of imitations were approved in 2018, and Livzon Group declared for listing under the new classification, which is expected to win the first domestic review.
At present, Livzon Group has reviewed 3 products (including deemed review).
Among them, tinidazole tablets have been reviewed by 3 companies.
If it is included in the fifth batch of national procurement, it is expected to help the company participate in the bidding for the first time.
In addition, in terms of product consistency evaluation, omeprazole sodium for injection has been reviewed by 3 companies, and isosorbide mononitrate tablets have been reviewed by 2 companies.
If these two varieties are finally selected, and Li Zhuneng has reviewed before the bid opening, and it is also expected to add another bargaining chip to the company.
The follow-up situation is worth looking forward to.
Among them, tinidazole tablets have been reviewed by 3 companies.
If it is included in the fifth batch of national procurement, it is expected to help the company participate in the bidding for the first time.
In addition, in terms of product consistency evaluation, omeprazole sodium for injection has been reviewed by 3 companies, and isosorbide mononitrate tablets have been reviewed by 2 companies.
If these two varieties are finally selected, and Li Zhuneng has reviewed before the bid opening, and it is also expected to add another bargaining chip to the company.
The follow-up situation is worth looking forward to.
Conclusion
Livzon Group has blossomed in the fields of chemical medicines, Chinese patent medicines, biological medicines, bulk medicines, diagnostic reagents, etc.
, while deepening the market, it continues to strengthen innovation and research and development.
The brokerage expects that the company's net profit in 2021 will be close to 2 billion yuan, and the target for 2022 The market value is 70 billion yuan.
With the continuous realization of the biological drugs and complex preparations under research, it will help the company to climb to the peak of the market value of 100 billion yuan in the future.
, while deepening the market, it continues to strengthen innovation and research and development.
The brokerage expects that the company's net profit in 2021 will be close to 2 billion yuan, and the target for 2022 The market value is 70 billion yuan.
With the continuous realization of the biological drugs and complex preparations under research, it will help the company to climb to the peak of the market value of 100 billion yuan in the future.
Source: company announcement, Minet database
Statistics are as of March 26, if there are any omissions, please correct me.
Medical Network, March 31, News Livzon Group ushered in a bumper performance in 2020, operating income exceeded 10 billion for the first time, a year-on-year increase of 12.
10%; net profit was 1.
715 billion yuan, a year-on-year increase of 31.
63%, and expected cash dividends of 1.
165 billion yuan, a year-on-year increase An increase of 8.
39%.
In recent years, Livzon Group has entered a new stage of innovation-driven development.
The innovative drug ilaprazole and leuprolide acetate microspheres for injection of high-barrier complex preparations have continued to grow rapidly, and have now grown into more than 1 billion varieties.
Become a powerful engine for the company's rapid development.
In 2021, the group's multiple biological drugs and microsphere varieties will enter the harvest period.
10%; net profit was 1.
715 billion yuan, a year-on-year increase of 31.
63%, and expected cash dividends of 1.
165 billion yuan, a year-on-year increase An increase of 8.
39%.
In recent years, Livzon Group has entered a new stage of innovation-driven development.
The innovative drug ilaprazole and leuprolide acetate microspheres for injection of high-barrier complex preparations have continued to grow rapidly, and have now grown into more than 1 billion varieties.
Become a powerful engine for the company's rapid development.
In 2021, the group's multiple biological drugs and microsphere varieties will enter the harvest period.
Revenue breaks tens of billions for the first time, and the exclusive variety "Rocket-style" soars
In 2020, the sales revenue of Livzon Group's chemical preparation products was 5.
4 billion yuan, an increase of 9.
56% year-on-year, accounting for 51.
64% of total revenue; the sales revenue of traditional Chinese medicine preparation products was 1.
2 billion yuan, a year-on-year decrease of 5.
78%, accounting for 11.
54% of total revenue.
%; The sales revenue of APIs and intermediate products was 2.
4 billion yuan, an increase of 3.
84% year-on-year, accounting for 23.
32% of total revenue; the sales revenue of diagnostic reagents and equipment was 1.
4 billion yuan, an increase of 83.
29% year-on-year, accounting for 13.
22% of total revenue %.
4 billion yuan, an increase of 9.
56% year-on-year, accounting for 51.
64% of total revenue; the sales revenue of traditional Chinese medicine preparation products was 1.
2 billion yuan, a year-on-year decrease of 5.
78%, accounting for 11.
54% of total revenue.
%; The sales revenue of APIs and intermediate products was 2.
4 billion yuan, an increase of 3.
84% year-on-year, accounting for 23.
32% of total revenue; the sales revenue of diagnostic reagents and equipment was 1.
4 billion yuan, an increase of 83.
29% year-on-year, accounting for 13.
22% of total revenue %.
In recent years, Franc Group's diagnostics business segment revenues rising fast, in order to further enhance the profitability and competitiveness, the company decided to split Franc reagents to the Shenzhen Stock Exchange GEM board listed, the latest news shows, Franc reagent respectively in 2020 In November 2015 and February 2021, we went through the counseling filing registration and submitted the first mid-term counseling filing report.
Table 1: Livzon Group's preparation products with sales exceeding 100 million yuan in 2020 (unit: million yuan)
Source: Company Annual Report
In 2020, the company's sales revenue from multiple preparations showed a skyrocketing trend: the exclusive innovative drug ilaprazole successfully entered the 1 billion lineup, and sales revenue increased by 81.
20%.
Among them, the sales revenue of ilaprazole enteric-coated tablets was 950 million yuan, an increase of 8.
84% year-on-year; ilaprazole sodium for injection was approved for listing in 2018 and successfully entered the national medical insurance catalog in 2019, and the sales revenue that year broke 1 Billion yuan, an increase of 667.
09% year-on-year, and sales revenue in 2020 will be 820 million yuan, an increase of 672.
61% year-on-year The rapid growth for two consecutive years has not stopped the Livzon Group.
It is reported that the clinical trial of the new indication of ilaprazole sodium for injection "prevention of stress ulcer bleeding in critically ill patients" has been awarded the NMPA in December 2020.
Approved; in addition, the company revealed that it will invest 200 million yuan in the "in-depth development and industrialization upgrade project of ilaprazole series of innovative products" in the next four years.
This exclusive product is expected to continue to grow and become stronger.
20%.
Among them, the sales revenue of ilaprazole enteric-coated tablets was 950 million yuan, an increase of 8.
84% year-on-year; ilaprazole sodium for injection was approved for listing in 2018 and successfully entered the national medical insurance catalog in 2019, and the sales revenue that year broke 1 Billion yuan, an increase of 667.
09% year-on-year, and sales revenue in 2020 will be 820 million yuan, an increase of 672.
61% year-on-year The rapid growth for two consecutive years has not stopped the Livzon Group.
It is reported that the clinical trial of the new indication of ilaprazole sodium for injection "prevention of stress ulcer bleeding in critically ill patients" has been awarded the NMPA in December 2020.
Approved; in addition, the company revealed that it will invest 200 million yuan in the "in-depth development and industrialization upgrade project of ilaprazole series of innovative products" in the next four years.
This exclusive product is expected to continue to grow and become stronger.
Figure 1: The specific investment plan for the in-depth development and industrialization upgrade of ilaprazole series of innovative products (unit: ten thousand yuan)
Source: Company announcement
Antiviral particles are the exclusive proprietary Chinese medicine product of Sichuan Everbright Pharmaceutical, a subsidiary of Sichuan Everbright Pharmaceutical.
This product has been included in the guidelines for the diagnosis and treatment of new coronary pneumonia during the epidemic.
The company organized a number of online academic promotion activities, and the product coverage of chain pharmacies and other terminals continued to expand.
2020 The sales of anti-viral particles grew against the current trend, with an increase of over 50%.
This product has been included in the guidelines for the diagnosis and treatment of new coronary pneumonia during the epidemic.
The company organized a number of online academic promotion activities, and the product coverage of chain pharmacies and other terminals continued to expand.
2020 The sales of anti-viral particles grew against the current trend, with an increase of over 50%.
Since the medical insurance of Shenqi Fuzheng injection, the exclusive Chinese patent medicine, was restricted in 2017, the company's traditional Chinese medicine preparations segment revenue began to decline, and the growth rates from 2018 to 2020 were -25.
07%, -16.
39%, and -5.
78%, respectively.
Thanks to the pull of anti-viral particles, performance is picking up.
On March 22, Livzon Group announced the acquisition of a 40% stake in Tianjin Tongrentang for 724 million yuan, hoping to cooperate with it in the development of Chinese medicine business.
According to the data of Minai.
com, it is in the public hospitals of cities in China and county-level public hospitals .
Hospitals, urban communities and township health centers (Chinese public medical institutions for short) terminals, Tianjin Tongrentang’s proprietary Chinese medicine products mainly involve drugs for diseases such as the urinary system, cardiovascular and cerebrovascular, respiratory systems, and musculoskeletal systems .
At present, the company has launched counseling on the market.
In the future, Livzon Group can also realize corresponding investment income through its cash dividends or initial public offerings.
07%, -16.
39%, and -5.
78%, respectively.
Thanks to the pull of anti-viral particles, performance is picking up.
On March 22, Livzon Group announced the acquisition of a 40% stake in Tianjin Tongrentang for 724 million yuan, hoping to cooperate with it in the development of Chinese medicine business.
According to the data of Minai.
com, it is in the public hospitals of cities in China and county-level public hospitals .
Hospitals, urban communities and township health centers (Chinese public medical institutions for short) terminals, Tianjin Tongrentang’s proprietary Chinese medicine products mainly involve drugs for diseases such as the urinary system, cardiovascular and cerebrovascular, respiratory systems, and musculoskeletal systems .
At present, the company has launched counseling on the market.
In the future, Livzon Group can also realize corresponding investment income through its cash dividends or initial public offerings.
Livzon Group has entered a harvest period in the field of neurological drugs.
The sales revenue of the first domestic imitation fluvoxamine maleate tablets and the exclusive product piperopilone hydrochloride tablets will increase by 33.
00% and 101.
78% in 2020.
Piperone hydrochloride tablets are a new product in the 2019 National Medical Insurance Catalog.
The sales revenue that year was about 50 million yuan, and it will break through the 100 million yuan mark in 2020.
Brokers predict that neurological drugs are expected to become another independent specialty line besides the company's assisted reproduction.
The sales revenue of the first domestic imitation fluvoxamine maleate tablets and the exclusive product piperopilone hydrochloride tablets will increase by 33.
00% and 101.
78% in 2020.
Piperone hydrochloride tablets are a new product in the 2019 National Medical Insurance Catalog.
The sales revenue that year was about 50 million yuan, and it will break through the 100 million yuan mark in 2020.
Brokers predict that neurological drugs are expected to become another independent specialty line besides the company's assisted reproduction.
R&D investment of nearly 1 billion, innovative biological drugs, high-barrier complex preparations welcome a bumper period
In 2020, the total R&D investment of Livzon Group is about 990 million yuan, an increase of 19.
55% year-on-year, and the proportion of the group's total revenue has increased to 9.
41%; the number of R&D personnel has increased by 24.
97% over 2019, and the proportion of R&D personnel has also increased to 10.
89 %.
Livzon Group continues to promote product innovation and upgrading, focusing on unmet clinical needs, focusing on innovative drugs and high-barrier complex preparations.
At present, R&D projects are progressing in an orderly manner, and the harvest period for innovation and transformation is approaching.
55% year-on-year, and the proportion of the group's total revenue has increased to 9.
41%; the number of R&D personnel has increased by 24.
97% over 2019, and the proportion of R&D personnel has also increased to 10.
89 %.
Livzon Group continues to promote product innovation and upgrading, focusing on unmet clinical needs, focusing on innovative drugs and high-barrier complex preparations.
At present, R&D projects are progressing in an orderly manner, and the harvest period for innovation and transformation is approaching.
Table 2: The latest situation of Livzon Group's focus on researching innovative biological drugs
Source: China Drug Clinical Trial Publicity Library of Meinenet
At present, the Livzon Group’s biopharmaceutical platform has focused on a number of core projects.
Among them, the recombinant human chorionic gonadotropin for injection that has been declared for listing has completed the production site verification and registration inspection.
It is expected to win the first domestic one this year, and it is also registered overseas.
During the simultaneous development, the company stated that it has made preparations for the listing of the product and the post-listing marketing work, and the market potential is worth looking forward to.
Among them, the recombinant human chorionic gonadotropin for injection that has been declared for listing has completed the production site verification and registration inspection.
It is expected to win the first domestic one this year, and it is also registered overseas.
During the simultaneous development, the company stated that it has made preparations for the listing of the product and the post-listing marketing work, and the market potential is worth looking forward to.
Recombinant humanized anti-human IL-6R monoclonal antibody injection has all entered the phase III clinical trial group, and the recombinant humanized anti-PD-1 monoclonal antibody for injection has entered the phase II clinical trial.
In addition, the company announced on March 24 that the The "recombinant new coronavirus fusion protein vaccine" developed by Rizumab has obtained clinical approval, which is expected to help the company improve its market position in the field of biopharmaceuticals.
It is reported that Livzon Group is also continuously advancing the construction of ADC technology platform and new CAR-T technology platform, and it is expected to launch related new products in the future.
In addition, the company announced on March 24 that the The "recombinant new coronavirus fusion protein vaccine" developed by Rizumab has obtained clinical approval, which is expected to help the company improve its market position in the field of biopharmaceuticals.
It is reported that Livzon Group is also continuously advancing the construction of ADC technology platform and new CAR-T technology platform, and it is expected to launch related new products in the future.
Table 3: The latest situation of Livzon Group's microsphere products under development
Source: China Drug Clinical Trial Publicity Library of Meinenet
The sales revenue of Livzon Group's first high-barrier complex preparation injection leuprorelin acetate microspheres exceeded 1 billion yuan for the first time in 2020.
It is the market leading brand of this variety.
The supplementary application for consistency evaluation is currently under review and approval.
It is the market leading brand of this variety.
The supplementary application for consistency evaluation is currently under review and approval.
The dazzling transcript stimulated new impetus for the company’s research and development.
Triptorelin acetate microspheres for injection (1 month sustained release) are in the phase III clinical trial data compilation stage, and octreotide acetate microspheres for injection (1 month sustained release) are in the stage of data compilation.
Release) BE trials have started, and the two major products are expected to be approved for marketing in 2022; Aripiprazole Microspheres for Injection (1 month sustained release) are undergoing clinical trials, and Leuprolide Acetate Microspheres for Injection (3 (Monthly release) Phase I clinical trials are carried out as planned, and Phase III clinical trials have completed genetic filing.
.
.
As the company's microsphere products are successively listed, Livzon Group's domestic leading position in this field will become more prominent.
Triptorelin acetate microspheres for injection (1 month sustained release) are in the phase III clinical trial data compilation stage, and octreotide acetate microspheres for injection (1 month sustained release) are in the stage of data compilation.
Release) BE trials have started, and the two major products are expected to be approved for marketing in 2022; Aripiprazole Microspheres for Injection (1 month sustained release) are undergoing clinical trials, and Leuprolide Acetate Microspheres for Injection (3 (Monthly release) Phase I clinical trials are carried out as planned, and Phase III clinical trials have completed genetic filing.
.
.
As the company's microsphere products are successively listed, Livzon Group's domestic leading position in this field will become more prominent.
10 million to mention the first imitation in China, the "national procurement special train" is expected to get on the train?
Table 4: Status of Livzon Group's approved products in 2020
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In 2020, Livzon Group’s generic drugs ushered in a number of good news: Dantrolene sodium for injection and mixed glycoelectrolyte injection were approved for marketing, and tinidazole tablets and amlodipine besylate capsules were approved for consistency evaluation.
After 10 years of research and development, dantrolene sodium for injection was applied for the listing of 3 types of generics in February 2019.
It was included in the priority review in April of the same year.
The reason was that it was a “rare disease drug”.
In October 2020, it won the first imitation in China.
Symptoms are used to prevent and treat malignant high fever.
Malignant hyperthermia is a rare disease.
In the absence of specific treatment drugs, general clinical cooling measures are difficult to control the increase in body temperature, which can eventually lead to death of the patient.
It is reported that the Livzon Group has invested about 17.
223 million yuan in research and development expenses in the dantrolene sodium injection project.
It was included in the priority review in April of the same year.
The reason was that it was a “rare disease drug”.
In October 2020, it won the first imitation in China.
Symptoms are used to prevent and treat malignant high fever.
Malignant hyperthermia is a rare disease.
In the absence of specific treatment drugs, general clinical cooling measures are difficult to control the increase in body temperature, which can eventually lead to death of the patient.
It is reported that the Livzon Group has invested about 17.
223 million yuan in research and development expenses in the dantrolene sodium injection project.
Table 5: Status of generic drugs (except Microspheres) under review by Livzon Group since 2019
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In 2020, the company declared cetrorelix acetate for injection and voriconazole for injection (0.
2g) to be marketed.
Cetrorelix is a synthetic gonadotropin releasing hormone antagonist.
The original research company is Merck Serono.
The disease is to prevent premature ovulation for patients undergoing controlled ovarian stimulation, and then carry out egg collection and assisted reproductive technology treatment.
It has been listed in 45 countries including Europe and entered the Chinese market in 2010.
The original product will be in China in 2019.
The terminal sales of public medical institutions are close to 250 million yuan.
Shenzhen Hanyu Pharmaceutical's 6 types of imitations were approved in 2018, and Livzon Group declared for listing under the new classification, which is expected to win the first domestic review.
2g) to be marketed.
Cetrorelix is a synthetic gonadotropin releasing hormone antagonist.
The original research company is Merck Serono.
The disease is to prevent premature ovulation for patients undergoing controlled ovarian stimulation, and then carry out egg collection and assisted reproductive technology treatment.
It has been listed in 45 countries including Europe and entered the Chinese market in 2010.
The original product will be in China in 2019.
The terminal sales of public medical institutions are close to 250 million yuan.
Shenzhen Hanyu Pharmaceutical's 6 types of imitations were approved in 2018, and Livzon Group declared for listing under the new classification, which is expected to win the first domestic review.
At present, Livzon Group has reviewed 3 products (including deemed review).
Among them, tinidazole tablets have been reviewed by 3 companies.
If it is included in the fifth batch of national procurement, it is expected to help the company participate in the bidding for the first time.
In addition, in terms of product consistency evaluation, omeprazole sodium for injection has been reviewed by 3 companies, and isosorbide mononitrate tablets have been reviewed by 2 companies.
If these two varieties are finally selected, and Li Zhuneng has reviewed before the bid opening, and it is also expected to add another bargaining chip to the company.
The follow-up situation is worth looking forward to.
Among them, tinidazole tablets have been reviewed by 3 companies.
If it is included in the fifth batch of national procurement, it is expected to help the company participate in the bidding for the first time.
In addition, in terms of product consistency evaluation, omeprazole sodium for injection has been reviewed by 3 companies, and isosorbide mononitrate tablets have been reviewed by 2 companies.
If these two varieties are finally selected, and Li Zhuneng has reviewed before the bid opening, and it is also expected to add another bargaining chip to the company.
The follow-up situation is worth looking forward to.
Conclusion
Livzon Group has blossomed in the fields of chemical medicines, Chinese patent medicines, biological medicines, bulk medicines, diagnostic reagents, etc.
, while deepening the market, it continues to strengthen innovation and research and development.
The brokerage expects that the company's net profit in 2021 will be close to 2 billion yuan, and the target for 2022 The market value is 70 billion yuan.
With the continuous realization of the biological drugs and complex preparations under research, it will help the company to climb to the peak of the market value of 100 billion yuan in the future.
, while deepening the market, it continues to strengthen innovation and research and development.
The brokerage expects that the company's net profit in 2021 will be close to 2 billion yuan, and the target for 2022 The market value is 70 billion yuan.
With the continuous realization of the biological drugs and complex preparations under research, it will help the company to climb to the peak of the market value of 100 billion yuan in the future.
Source: company announcement, Minet database
Statistics are as of March 26, if there are any omissions, please correct me.
Medical Network, March 31, News Livzon Group ushered in a bumper performance in 2020, operating income exceeded 10 billion for the first time, a year-on-year increase of 12.
10%; net profit was 1.
715 billion yuan, a year-on-year increase of 31.
63%, and expected cash dividends of 1.
165 billion yuan, a year-on-year increase An increase of 8.
39%.
In recent years, Livzon Group has entered a new stage of innovation-driven development.
The innovative drug ilaprazole and leuprolide acetate microspheres for injection of high-barrier complex preparations have continued to grow rapidly, and have now grown into more than 1 billion varieties.
Become a powerful engine for the company's rapid development.
In 2021, the group's multiple biological drugs and microsphere varieties will enter the harvest period.
10%; net profit was 1.
715 billion yuan, a year-on-year increase of 31.
63%, and expected cash dividends of 1.
165 billion yuan, a year-on-year increase An increase of 8.
39%.
In recent years, Livzon Group has entered a new stage of innovation-driven development.
The innovative drug ilaprazole and leuprolide acetate microspheres for injection of high-barrier complex preparations have continued to grow rapidly, and have now grown into more than 1 billion varieties.
Become a powerful engine for the company's rapid development.
In 2021, the group's multiple biological drugs and microsphere varieties will enter the harvest period.
Revenue breaks tens of billions for the first time, and the exclusive variety "Rocket-style" soars
Revenue breaks tens of billions for the first time, and the exclusive variety "Rocket-style" soars In 2020, the sales revenue of Livzon Group's chemical preparation products was 5.
4 billion yuan, an increase of 9.
56% year-on-year, accounting for 51.
64% of total revenue; the sales revenue of traditional Chinese medicine preparation products was 1.
2 billion yuan, a year-on-year decrease of 5.
78%, accounting for 11.
54% of total revenue.
%; The sales revenue of APIs and intermediate products was 2.
4 billion yuan, an increase of 3.
84% year-on-year, accounting for 23.
32% of total revenue; the sales revenue of diagnostic reagents and equipment was 1.
4 billion yuan, an increase of 83.
29% year-on-year, accounting for 13.
22% of total revenue %.
4 billion yuan, an increase of 9.
56% year-on-year, accounting for 51.
64% of total revenue; the sales revenue of traditional Chinese medicine preparation products was 1.
2 billion yuan, a year-on-year decrease of 5.
78%, accounting for 11.
54% of total revenue.
%; The sales revenue of APIs and intermediate products was 2.
4 billion yuan, an increase of 3.
84% year-on-year, accounting for 23.
32% of total revenue; the sales revenue of diagnostic reagents and equipment was 1.
4 billion yuan, an increase of 83.
29% year-on-year, accounting for 13.
22% of total revenue %.
In recent years, Franc Group's diagnostics business segment revenues rising fast, in order to further enhance the profitability and competitiveness, the company decided to split Franc reagents to the Shenzhen Stock Exchange GEM board listed, the latest news shows, Franc reagent respectively in 2020 In November 2015 and February 2021, we went through the counseling filing registration and submitted the first mid-term counseling filing report.
Venture Venture Venture Table 1: Livzon Group's preparation products with sales exceeding 100 million yuan in 2020 (unit: million yuan)
Source: Company Annual Report
In 2020, the company's sales revenue from multiple preparations showed a skyrocketing trend: the exclusive innovative drug ilaprazole successfully entered the 1 billion lineup, and sales revenue increased by 81.
20%.
Among them, the sales revenue of ilaprazole enteric-coated tablets was 950 million yuan, an increase of 8.
84% year-on-year; ilaprazole sodium for injection was approved for listing in 2018 and successfully entered the national medical insurance catalog in 2019, and the sales revenue that year broke 1 Billion yuan, an increase of 667.
09% year-on-year, and sales revenue in 2020 will be 820 million yuan, an increase of 672.
61% year-on-year The rapid growth for two consecutive years has not stopped the Livzon Group.
It is reported that the clinical trial of the new indication of ilaprazole sodium for injection "prevention of stress ulcer bleeding in critically ill patients" has been awarded the NMPA in December 2020.
Approved; in addition, the company revealed that it will invest 200 million yuan in the "in-depth development and industrialization upgrade project of ilaprazole series of innovative products" in the next four years.
This exclusive product is expected to continue to grow and become stronger.
20%.
Among them, the sales revenue of ilaprazole enteric-coated tablets was 950 million yuan, an increase of 8.
84% year-on-year; ilaprazole sodium for injection was approved for listing in 2018 and successfully entered the national medical insurance catalog in 2019, and the sales revenue that year broke 1 Billion yuan, an increase of 667.
09% year-on-year, and sales revenue in 2020 will be 820 million yuan, an increase of 672.
61% year-on-year The rapid growth for two consecutive years has not stopped the Livzon Group.
It is reported that the clinical trial of the new indication of ilaprazole sodium for injection "prevention of stress ulcer bleeding in critically ill patients" has been awarded the NMPA in December 2020.
Approved; in addition, the company revealed that it will invest 200 million yuan in the "in-depth development and industrialization upgrade project of ilaprazole series of innovative products" in the next four years.
This exclusive product is expected to continue to grow and become stronger.
Figure 1: The specific investment plan for the in-depth development and industrialization upgrade of ilaprazole series of innovative products (unit: ten thousand yuan)
Source: Company announcement
Antiviral particles are the exclusive proprietary Chinese medicine product of Sichuan Everbright Pharmaceutical, a subsidiary of Sichuan Everbright Pharmaceutical.
This product has been included in the guidelines for the diagnosis and treatment of new coronary pneumonia during the epidemic.
The company organized a number of online academic promotion activities, and the product coverage of chain pharmacies and other terminals continued to expand.
2020 The sales of anti-viral particles grew against the current trend, with an increase of over 50%.
Pharmacy pharmacy pharmacyThis product has been included in the guidelines for the diagnosis and treatment of new coronary pneumonia during the epidemic.
The company organized a number of online academic promotion activities, and the product coverage of chain pharmacies and other terminals continued to expand.
2020 The sales of anti-viral particles grew against the current trend, with an increase of over 50%.
Since the medical insurance of Shenqi Fuzheng injection, the exclusive Chinese patent medicine, was restricted in 2017, the company's traditional Chinese medicine preparations segment revenue began to decline, and the growth rates from 2018 to 2020 were -25.
07%, -16.
39%, and -5.
78%, respectively.
Thanks to the pull of anti-viral particles, performance is picking up.
On March 22, Livzon Group announced the acquisition of a 40% stake in Tianjin Tongrentang for 724 million yuan, hoping to cooperate with it in the development of Chinese medicine business.
According to the data of Minai.
com, it is in the public hospitals of cities in China and county-level public hospitals .
Hospitals, urban communities and township health centers (Chinese public medical institutions for short) terminals, Tianjin Tongrentang’s proprietary Chinese medicine products mainly involve drugs for diseases such as the urinary system, cardiovascular and cerebrovascular, respiratory systems, and musculoskeletal systems .
At present, the company has launched counseling on the market.
In the future, Livzon Group can also realize corresponding investment income through its cash dividends or initial public offerings.
Hospital hospital hospital disease disease disease07%, -16.
39%, and -5.
78%, respectively.
Thanks to the pull of anti-viral particles, performance is picking up.
On March 22, Livzon Group announced the acquisition of a 40% stake in Tianjin Tongrentang for 724 million yuan, hoping to cooperate with it in the development of Chinese medicine business.
According to the data of Minai.
com, it is in the public hospitals of cities in China and county-level public hospitals .
Hospitals, urban communities and township health centers (Chinese public medical institutions for short) terminals, Tianjin Tongrentang’s proprietary Chinese medicine products mainly involve drugs for diseases such as the urinary system, cardiovascular and cerebrovascular, respiratory systems, and musculoskeletal systems .
At present, the company has launched counseling on the market.
In the future, Livzon Group can also realize corresponding investment income through its cash dividends or initial public offerings.
Livzon Group has entered a harvest period in the field of neurological drugs.
The sales revenue of the first domestic imitation fluvoxamine maleate tablets and the exclusive product piperopilone hydrochloride tablets will increase by 33.
00% and 101.
78% in 2020.
Piperone hydrochloride tablets are a new product in the 2019 National Medical Insurance Catalog.
The sales revenue that year was about 50 million yuan, and it will break through the 100 million yuan mark in 2020.
Brokers predict that neurological drugs are expected to become another independent specialty line besides the company's assisted reproduction.
The sales revenue of the first domestic imitation fluvoxamine maleate tablets and the exclusive product piperopilone hydrochloride tablets will increase by 33.
00% and 101.
78% in 2020.
Piperone hydrochloride tablets are a new product in the 2019 National Medical Insurance Catalog.
The sales revenue that year was about 50 million yuan, and it will break through the 100 million yuan mark in 2020.
Brokers predict that neurological drugs are expected to become another independent specialty line besides the company's assisted reproduction.
R&D investment of nearly 1 billion, innovative biological drugs, high-barrier complex preparations welcome a bumper period
R&D investment of nearly 1 billion, innovative biological drugs, high-barrier complex preparations welcome a bumper period In 2020, the total R&D investment of Livzon Group is about 990 million yuan, an increase of 19.
55% year-on-year, and the proportion of the group's total revenue has increased to 9.
41%; the number of R&D personnel has increased by 24.
97% over 2019, and the proportion of R&D personnel has also increased to 10.
89 %.
Livzon Group continues to promote product innovation and upgrading, focusing on unmet clinical needs, focusing on innovative drugs and high-barrier complex preparations.
At present, R&D projects are progressing in an orderly manner, and the harvest period for innovation and transformation is approaching.
55% year-on-year, and the proportion of the group's total revenue has increased to 9.
41%; the number of R&D personnel has increased by 24.
97% over 2019, and the proportion of R&D personnel has also increased to 10.
89 %.
Livzon Group continues to promote product innovation and upgrading, focusing on unmet clinical needs, focusing on innovative drugs and high-barrier complex preparations.
At present, R&D projects are progressing in an orderly manner, and the harvest period for innovation and transformation is approaching.
Table 2: The latest situation of Livzon Group's focus on researching innovative biological drugs
Source: China Drug Clinical Trial Publicity Library of Meinenet
At present, the Livzon Group’s biopharmaceutical platform has focused on a number of core projects.
Among them, the recombinant human chorionic gonadotropin for injection that has been declared for listing has completed the production site verification and registration inspection.
It is expected to win the first domestic one this year, and it is also registered overseas.
During the simultaneous development, the company stated that it has made preparations for the listing of the product and the post-listing marketing work, and the market potential is worth looking forward to.
Among them, the recombinant human chorionic gonadotropin for injection that has been declared for listing has completed the production site verification and registration inspection.
It is expected to win the first domestic one this year, and it is also registered overseas.
During the simultaneous development, the company stated that it has made preparations for the listing of the product and the post-listing marketing work, and the market potential is worth looking forward to.
Recombinant humanized anti-human IL-6R monoclonal antibody injection has all entered the phase III clinical trial group, and the recombinant humanized anti-PD-1 monoclonal antibody for injection has entered the phase II clinical trial.
In addition, the company announced on March 24 that the The "recombinant new coronavirus fusion protein vaccine" developed by Rizumab has obtained clinical approval, which is expected to help the company improve its market position in the field of biopharmaceuticals.
It is reported that Livzon Group is also continuously advancing the construction of ADC technology platform and new CAR-T technology platform, and it is expected to launch related new products in the future.
In addition, the company announced on March 24 that the The "recombinant new coronavirus fusion protein vaccine" developed by Rizumab has obtained clinical approval, which is expected to help the company improve its market position in the field of biopharmaceuticals.
It is reported that Livzon Group is also continuously advancing the construction of ADC technology platform and new CAR-T technology platform, and it is expected to launch related new products in the future.
Table 3: The latest situation of Livzon Group's microsphere products under development
Source: China Drug Clinical Trial Publicity Library of Meinenet
The sales revenue of Livzon Group's first high-barrier complex preparation injection leuprorelin acetate microspheres exceeded 1 billion yuan for the first time in 2020.
It is the market leading brand of this variety.
The supplementary application for consistency evaluation is currently under review and approval.
It is the market leading brand of this variety.
The supplementary application for consistency evaluation is currently under review and approval.
The dazzling transcript stimulated new impetus for the company’s research and development.
Triptorelin acetate microspheres for injection (1 month sustained release) are in the phase III clinical trial data compilation stage, and octreotide acetate microspheres for injection (1 month sustained release) are in the stage of data compilation.
Release) BE trials have started, and the two major products are expected to be approved for marketing in 2022; Aripiprazole Microspheres for Injection (1 month sustained release) are undergoing clinical trials, and Leuprolide Acetate Microspheres for Injection (3 (Monthly release) Phase I clinical trials are carried out as planned, and Phase III clinical trials have completed genetic filing.
.
.
As the company's microsphere products are successively listed, Livzon Group's domestic leading position in this field will become more prominent.
Triptorelin acetate microspheres for injection (1 month sustained release) are in the phase III clinical trial data compilation stage, and octreotide acetate microspheres for injection (1 month sustained release) are in the stage of data compilation.
Release) BE trials have started, and the two major products are expected to be approved for marketing in 2022; Aripiprazole Microspheres for Injection (1 month sustained release) are undergoing clinical trials, and Leuprolide Acetate Microspheres for Injection (3 (Monthly release) Phase I clinical trials are carried out as planned, and Phase III clinical trials have completed genetic filing.
.
.
As the company's microsphere products are successively listed, Livzon Group's domestic leading position in this field will become more prominent.
10 million to mention the first imitation in China, the "national procurement special train" is expected to get on the train?
10 million to mention the first imitation in China, the "national procurement special train" is expected to get on the train? Table 4: Status of Livzon Group's approved products in 2020
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In 2020, Livzon Group’s generic drugs ushered in a number of good news: Dantrolene sodium for injection and mixed glycoelectrolyte injection were approved for marketing, and tinidazole tablets and amlodipine besylate capsules were approved for consistency evaluation.
After 10 years of research and development, dantrolene sodium for injection was applied for the listing of 3 types of generics in February 2019.
It was included in the priority review in April of the same year.
The reason was that it was a “rare disease drug”.
In October 2020, it won the first imitation in China.
Symptoms are used to prevent and treat malignant high fever.
Malignant hyperthermia is a rare disease.
In the absence of specific treatment drugs, general clinical cooling measures are difficult to control the increase in body temperature, which can eventually lead to death of the patient.
It is reported that the Livzon Group has invested about 17.
223 million yuan in research and development expenses in the dantrolene sodium injection project.
It was included in the priority review in April of the same year.
The reason was that it was a “rare disease drug”.
In October 2020, it won the first imitation in China.
Symptoms are used to prevent and treat malignant high fever.
Malignant hyperthermia is a rare disease.
In the absence of specific treatment drugs, general clinical cooling measures are difficult to control the increase in body temperature, which can eventually lead to death of the patient.
It is reported that the Livzon Group has invested about 17.
223 million yuan in research and development expenses in the dantrolene sodium injection project.
Table 5: Status of generic drugs (except Microspheres) under review by Livzon Group since 2019
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In 2020, the company declared cetrorelix acetate for injection and voriconazole for injection (0.
2g) to be marketed.
Cetrorelix is a synthetic gonadotropin releasing hormone antagonist.
The original research company is Merck Serono.
The disease is to prevent premature ovulation for patients undergoing controlled ovarian stimulation, and then carry out egg collection and assisted reproductive technology treatment.
It has been listed in 45 countries including Europe and entered the Chinese market in 2010.
The original product will be in China in 2019.
The terminal sales of public medical institutions are close to 250 million yuan.
Shenzhen Hanyu Pharmaceutical's 6 types of imitations were approved in 2018, and Livzon Group declared for listing under the new classification, which is expected to win the first domestic review.
Enterprise business enterprise2g) to be marketed.
Cetrorelix is a synthetic gonadotropin releasing hormone antagonist.
The original research company is Merck Serono.
The disease is to prevent premature ovulation for patients undergoing controlled ovarian stimulation, and then carry out egg collection and assisted reproductive technology treatment.
It has been listed in 45 countries including Europe and entered the Chinese market in 2010.
The original product will be in China in 2019.
The terminal sales of public medical institutions are close to 250 million yuan.
Shenzhen Hanyu Pharmaceutical's 6 types of imitations were approved in 2018, and Livzon Group declared for listing under the new classification, which is expected to win the first domestic review.
At present, Livzon Group has reviewed 3 products (including deemed review).
Among them, tinidazole tablets have been reviewed by 3 companies.
If it is included in the fifth batch of national procurement, it is expected to help the company participate in the bidding for the first time.
In addition, in terms of product consistency evaluation, omeprazole sodium for injection has been reviewed by 3 companies, and isosorbide mononitrate tablets have been reviewed by 2 companies.
If these two varieties are finally selected, and Li Zhuneng has reviewed before the bid opening, and it is also expected to add another bargaining chip to the company.
The follow-up situation is worth looking forward to.
Among them, tinidazole tablets have been reviewed by 3 companies.
If it is included in the fifth batch of national procurement, it is expected to help the company participate in the bidding for the first time.
In addition, in terms of product consistency evaluation, omeprazole sodium for injection has been reviewed by 3 companies, and isosorbide mononitrate tablets have been reviewed by 2 companies.
If these two varieties are finally selected, and Li Zhuneng has reviewed before the bid opening, and it is also expected to add another bargaining chip to the company.
The follow-up situation is worth looking forward to.
Conclusion
Conclusion Livzon Group has blossomed in the fields of chemical medicines, Chinese patent medicines, biological medicines, bulk medicines, diagnostic reagents, etc.
, while deepening the market, it continues to strengthen innovation and research and development.
The brokerage expects that the company's net profit in 2021 will be close to 2 billion yuan, and the target for 2022 The market value is 70 billion yuan.
With the continuous realization of the biological drugs and complex preparations under research, it will help the company to climb to the peak of the market value of 100 billion yuan in the future.
, while deepening the market, it continues to strengthen innovation and research and development.
The brokerage expects that the company's net profit in 2021 will be close to 2 billion yuan, and the target for 2022 The market value is 70 billion yuan.
With the continuous realization of the biological drugs and complex preparations under research, it will help the company to climb to the peak of the market value of 100 billion yuan in the future.
Source: company announcement, Minet database
Statistics are as of March 26, if there are any omissions, please correct me.
